• Fri news: Gilead withdraws bladder cancer drug. Amgen and Intercept PDUFA date pushback. CVS replaces CEO. Supernus depression trial. AbbVie Parkinson’s approval. See more on our front page

Confusion at the top = 2012 Job Security

Anonymous

Guest
It should be relatively safe at B+L in 2012. With the new CEO and VPs just trying to survive at thier jobs by learning what an IOL and a contact lens are don't look for any layoffs of management anytime soon.
 












It should be relatively safe at B+L in 2012. With the new CEO and VPs just trying to survive at thier jobs by learning what an IOL and a contact lens are don't look for any layoffs of management anytime soon.

Very true. The distractions will be security for employees for a while. Combine that with the fact that ISTA (only company wanting BL) is now fighting off a hostile takeover from Valeant Pharmaceuticals means 2012 will be a safe year.